# Myoridge Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/myoridge-co

- Industry: Biotechnology
- Headquarters: Kyoto-shi, Japan
- Website: www.myoridge.co.jp/
- Total disclosed funding: $3.5M
- Latest round: Series C (Mar 1, 2021)
- Investors on record: 4

## About

Myoridge Co. Ltd., based in Kyoto-shi, Japan, specializes in developing advanced cell culture media for optimizing the growth of mesenchymal stem cells and T cells, serving the pharmaceutical and biotech industries.Founded in 2016 in Kyoto-shi, Japan, Myoridge Co. Ltd. focuses on innovative cell culture solutions. The company has completed 4 deals, with the most recent funding round occurring on April 25, 2022, where it raised JPY 600 million in a Series D round led by Mitsubishi Chemical Group, Sumitomo Chemical, and TOPPAN Holdings. The total amount raised to date is JPY 600 million, and the current company valuation stands at JPY 3043.765 million. The founder's history and previous ventures remain unspecified.Myoridge Co., Ltd. specializes in the development and commercialization of innovative cell culture media designed to optimize the growth and functionality of various cell types, particularly mesenchymal stem cells (MSCs) and T cells. Their core product line includes proprietary formulations that enhance tissue factor (TF) expression in MSCs, critical for applications in regenerative medicine and cellular therapies. These products cater to pharmaceutical, biotechnology, and academic research sectors, serving a diverse clientele involved in drug development, tissue engineering, and regenerative medicine across markets such as Japan, the United States, and Europe. Myoridge also offers consulting and optimization services to help clients tailor media solutions to address specific cell culture challenges.Myoridge's revenue model is primarily driven by direct sales of its proprietary media products and consulting services, focusing on a business-to-business (B2B) market. Transactions occur through established partnerships with research institutions and biotechnology companies, where clients purchase customized cell culture media formulations for applications, including drug screening and development. Flagship offerings like the patented CarmyA®-Monkey media and Ex-iPS Cell Medium provide revenue through one-time purchases and potentially long-term supply contracts. The pricing structure reflects the specialized nature of these products, aligning with the research and development budgets of institutional clients.In April 2022, Myoridge Co. Ltd. raised JPY 600 million in Series D funding to support the development of new cell culture-related products and services. The company plans to expand its market reach into new regions, including the United States and Europe, by 2023. The recent funding will be utilized to accelerate product development initiatives, enhancing their capacity to deliver specialized solutions that meet the evolving needs of the biotechnology sector.

## Funding rounds

- Series C, Mar 1, 2021, $2.3M — Kyoto University Innovation Capital, RFI Advisers
- Seed, Jan 17, 2020 — Regional Economy Vitalization Corporation of Japan (REVIC), Kyoto University Innovation Capital
- Series A, Apr 3, 2017, $1.1M — Beyond Next Ventures

## Investors

- Beyond Next Ventures (https://capitalatlas.ai/funds/beyond-next-ventures) — Series A
- Regional Economy Vitalization Corporation of Japan (REVIC) — Seed
- Kyoto University Innovation Capital (https://capitalatlas.ai/funds/kyoto-university-innovation-capital) — Seed, Series C
- RFI Advisers — Series C